Navigation Links
Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Date:3/17/2008

Potential to Develop Disease Treatments for Diabetic Kidney Disease and

Retinopathy, Each Multi-Billion-Dollar Drug Markets

JENKINTOWN, Pa., March 17 /PRNewswire/ -- Dynamis Therapeutics, Inc. announced the discovery of a new class of compounds that inhibit the production of RAGE, the Receptor for Advanced Glycation End Products (AGEs). Scientists expect that a RAGE inhibitor would be an important addition to the arsenal of drugs to treat diabetic kidney disease, retinopathy, microvascular disease, Alzheimer's, inflammatory diseases, some cancers, and aging.

A patent has been filed on the discovery.

A team of Dynamis Therapeutics' scientists significantly decreased kidney and retina RAGE in aged rats that were orally dosed with Dynamis Therapeutics' RAGE inhibitor for 32 weeks, as compared to non-treated rats. In addition, several other new compounds also inhibited RAGE in a variety of cells grown in culture.

In a parallel experiment, Dynamis Therapeutics' scientists increased the life span of mice by adding a RAGE inhibitor to their drinking water. The laboratory mice were divided into four groups: a control group treated only with water and three groups treated with varying doses of the RAGE inhibitor. The mice receiving the highest RAGE inhibitor dose lived, on average, 256 days longer than those receiving only water. Longevity increased proportionally with dosage strength.

Commented Dr. Annette Tobia, president and founder of Dynamis Therapeutics, Inc., "We are very excited about these results, since discovering RAGE inhibitors enables Dynamis Therapeutics to develop a treatment for diabetic kidney disease and blindness. Diabetes and its complications have become epidemic, not only in the United States, but worldwide. Retinopathy often leads to blindness. It would be a tremendous advance to eventually have a drug to treat such a serious disease."

Dynamis Therapeutics, Inc., located in Jenkintown, Pennsylvania (http://www.dynamis-therapeutics.com), develops products that treat chronic inflammatory conditions and accelerated aging diseases such as diabetic nephropathy and retinopathy.

Dynamis Therapeutics supports its research, in part, by marketing the MEG 21 product line of anti-aging and anti-wrinkling cosmetic skin care products to dermatologists, plastic surgeons, and aestheticians and by out-licensing the cosmetic applications of its breakthrough technology for fees and royalties.

Dynamis Therapeutics' technology is based on the discovery of an aging/inflammatory pathway that was made by its scientific founders while they were working at the Fox Chase Cancer Center in Philadelphia. The technology is exclusively licensed to Dynamis Therapeutics. Dynamis Therapeutics is presently preparing to file an IND with the FDA for a treatment for inflammation associated with dry eye.


'/>"/>
SOURCE Dynamis Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
2. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
3. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
4. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
7. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
8. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
9. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
10. Video: New Research Discovers Independent Brain Networks Control Human Walking
11. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
Breaking Medicine News(10 mins):